Anzeige
Mehr »
Dienstag, 07.04.2026 - Börsentäglich über 12.000 News
Diese Entwicklung im KI-Sektor könnte unterschätzt werden - und sie betrifft die Energieversorgung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MoCareTrust REIT closes $119M in healthcare property deals
MoExponent names new president and CFO, board chairman
MoIQSTEL reports 11.9% revenue growth for fiscal 2025
MoCognex completes sale of Japan trading unit for $11.9 million
MoFMC receives EU approval for Isoflex herbicide active ingredient
MoNeuronetics CFO Steven Pfanstiel to depart in May
MoClear Street raises Protagonist Therapeutics price target on drug potential
MoJefferies raises Cheniere Energy stock price target to $330 on EBITDA beat
MoOppenheimer cuts Soleno Therapeutics stock rating on acquisition
MoJefferies downgrades Las Vegas Sands on margin pressure due to strategy shift
MoTwilio Rises As Jefferies Upgrades To 'Buy', Sees $1.15B in its voice revenue by 2
MoPatterson-UTI reports 90 drilling rigs operating in March
MoOFA Group acquires 50% stake in QIKBIM intellectual property
MoTapestry appoints Pinterest CTO Matt Madrigal to board
MoSix Flags completes sale of six U.S. parks to EPR Properties
MoSilo Pharma receives European patent approval for stress prevention therapy
MoAmerican Integrity names Brian Foley as chief financial officer
MoWedbush raises Neurocrine Bio stock price target on acquisition
MoFreedom Broker initiates Garrett Motion stock with buy rating on turbo tech strength
MoVeradigm names Christian Greyenbuhl as chief financial officer
MoOutset Medical names Derick Elliott commercial chief
MoFluor secures contract for X-energy nuclear project in Texas
MoNeuronetics largest shareholder pushes for strategic review
MoOwlet CEO Jonathan Harris resigns, founder Kurt Workman returns
MoAscendis Pharma's YUVIWEL gains orphan drug exclusivity in U.S.